Case Reports

Man With Flu-like Symptoms
Sandarsh Kancherla, MD, Ankitkumar Patel, MD, MPH

Case Presentation

A 69 year-old male presents to the Emergency Department
with complaints of malaise, myalgias, rhinorrhea, increased
congestion, and occasional fevers for one week. The symptoms
have gradually worsened over the past week, and Tylenol has
minimally alleviated his symptoms. He denies exacerbating
factors. He denies any trauma, shortness of breath, chest pain,
or recent weight change. He has no sick contacts or recent
travel history.
Past medical history is significant for coronary artery disease
status post myocardial infarction and coronary artery bypass
graft in 2000, hypertension, hyperlipidemia, and atrial
fibrillation. Medications on admission include amiodarone,
aspirin, atorvastatin, docusate, losartan, metoprolol succinate
(XL), and warfarin. He does not smoke, drink alcohol, or use
illicit drugs.
On admission, temperature was 99.7, blood pressure was 118/72,
heart rate was 74, respiratory rate was 18, and oxygen saturation
was 96% on room air. Physical examination was significant for
dry mucosa and mild proximal muscle weakness. Initial labs
on admission revealed an elevated creatinine of 1.9; CBC, UA,
and LFTs were within normal limits. The patient was admitted
with the diagnosis of upper respiratory tract infection with
dehydration and started on intravenous fluids and supportive
therapy for flu-like symptoms.
Approximately 3 days after admission, his rhinnorhea and
congestion had resolved, but he complained of worsening
myalgias. Physical exam at that time revealed worsening
tenderness to palpation over his shoulder muscles and
proximal lower extremities, as well as 4/5 muscle strength
in his quadriceps and deltoids. He had difficulty standing
from a seated position. Range of motion of all extremities
was intact. At that time, it was revealed that his atorvastatin
dose had been increased from 40 mg to 80 mg approximately
6 months ago as an outpatient. The CPK level drawn shortly
thereafter was 5,317, supporting a diagnosis of statin-induced
myositis, which is a form of drug-induced myopathy. Upon
discontinuing his atorvastatin, his symptoms improved, and
CPK trended down until it was within normal limits.

Discussion

Drug-induced myopathy is among the most common causes of
muscle disease. Symptoms range from mild myalgias with or
without mild weakness, to chronic myopathy characterized by
severe weakness, to massive rhabdomyolysis with acute renal
failure.1
Drug-induced myopathy results from direct myotoxicity from
lipid-lowering drugs and other agents such as alcohol, cocaine,
glucocorticoids, antimalarials, and colchicine. 2 Statins are

considered effective and generally safe, but experience in clinical
practice suggests that muscle side effects are relatively common;
some of the side effects are severe enough to warrant discontinuation of statin therapy.
The mechanism by which statins cause muscle toxicity is not
well understood. They inhibit the conversion of HMG-CoA to
mevalonic acid, which is an important early step in cholesterol
synthesis. Statins can also decrease the synthesis of coenzyme
Q10 (CoQ10), which plays an important role in muscle cell
energy production.3 This pathway is thought to contribute
tostatin-induced muscle injury.
The onset of muscle symptoms is usually within weeks to months
after the initiation of statin therapy. Typically, the presentation
of statin-induced myopathy is very non-specific. It has a very
insidious onset and includes progressive weakness, generalized
pain, and fatigue. Myalgias and weakness generally resolve, and
serum creatinine kinase levels return to normal within days to
weeks upon discontinuation of statin therapy.
The muscle symptoms in patients taking statin therapy can range
from mild symptoms to severe symptoms. The incidence of mild
myalgias, defined as muscle ache or weakness without increases
in CPK levels, in patients taking statins ranges from 2 to 11
percent.4-5 Symptoms generally resolve within 2 to 3 weeks after
stopping a statin. Myositis, defined as a serum CPK elevation
more than 10 times normal in association with muscle symptoms,
occurs in less than 0.5% of patients.4-5 Rhabdomyolysis resulting
from severe muscle destruction is rarely seen and occurs in less
than 0.1 % of patients.6 Rhabdomyolysis has primarily been
seen when a statin is given concurrently with cyclosporine or
gemfibrozil.7
The risk of muscle injury due to statins appears to vary among
the different drug formulations. The risk of myopathy is lowest
with pravastatin (less than 0.1%) and fluvastatin.8 These two
medications are also less likely to cause drug interactions since
they are not extensively metabolized by CYP3A4. Patients
with acute or chronic renal failure, obstructive liver disease,
and hypothyroidism have increased susceptibility to statinassociated myopathy.
The risk of myopathy is much greater in patients who are also
taking drugs that inhibit CYP3A4, must notably cyclosporine,
gemfibrozil, macrolide antibiotics, itraconazole, and HIV protease
inhibitors. These drugs increase the serum concentration of the
statins. Initial studies of lovastatin and simvastatin showed
clinically significant myopathy in 13 to 30% of patients taking
cyclosporine.4 Approximately 5% of patients taking atorvastatin
or lovastatin in addition to gemfibrozil experience significant
myopathy.4,9 In contrast, pravastatin and fluvastatin, which are
not metabolized by CYP3A4, do not appear to increase the risk
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of myopathy when given with cyclosporine.10,11 This is a very
important consideration when treating transplant patients.
Routine monitoring of CPK levels is not recommended, but
it is useful to obtain a baseline serum CPK before initiation
of statin therapy for reference. Patients should be alerted to
the potential side effects of statins and report new onset of
myalgias or weakness to their physician. CPK levels may be
abnormal in conditions such as hypothyroidism, trauma, and
high impact sports. In general, a CPK level more than 10 times
the upper limit of normal, in the absence of other clinical risk
factors, is generally felt to be due to a statin. It is an indication
to discontinue the medication. If a patient experiences muscle
myopathy on a statin, with the exception of rhabdomyolysis,
the statin should be discontinued until symptoms resolve. It is
reasonable to consider restarting pravastatin or fluvastatin with
careful monitoring. In the case of rhabdomyolysis, the statin
should be discontinued indefinitely. If muscle toxicity occurs
while on pravastatin or fluvastatin, a trial of CoQ10 supplementation may be initiated, although there is only limited evidence
for its benefit.12
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